Reports Q4 revenue $28.87M, consensus $28.9M. “We enter 2026 standing on a strong foundation for growth, well capitalized, and with a highly differentiated platform to help healthcare providers transform their clinical, operational and financial outcomes by insourcing dialysis with Outset,” said Leslie Trigg, chair and CEO.
Claim 30% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on OM:
- OM Earnings Report this Week: Is It a Buy, Ahead of Earnings?
- Outset Medical Wins FDA Clearance for Next-Gen Tablo System
- Outset Medical says next-generation Tablo platform receives FDA clearance
- Outset Medical Previews 2025 Results and Adds Director
- Outset Medical reports Q4 revenue $28.9M, consensus $26.15M